Pediatrix Swings to Profit on Impairment Absence, Cash Surges

TL;DR

**MD is back in the black, but revenue dips suggest a cautious buy on this turnaround story.**

AI Summary

Pediatrix Medical Group, Inc. (MD) reported a significant turnaround for the nine months ended September 30, 2025, with net income reaching $131.705 million, a stark contrast to the net loss of $129.549 million in the prior year. This improvement was driven by a substantial increase in income from operations to $160.019 million, up from a loss of $108.004 million in 2024, largely due to the absence of goodwill impairment ($154.243 million in 2024) and long-lived asset impairments ($27.791 million in 2024). However, net revenue for the nine-month period decreased by 5.99% to $1.420 billion from $1.511 billion in 2024, primarily due to lower net patient service revenue and hospital contract administrative fees. For the three months ended September 30, 2025, net income surged to $71.708 million from $19.441 million in 2024, despite a 3.57% decline in net revenue to $492.875 million. The company also saw a notable increase in cash and cash equivalents to $340.059 million as of September 30, 2025, from $229.940 million at December 31, 2024, reflecting strong net cash provided by operating activities of $156.989 million. Strategic outlook includes managing a joint venture and continued focus on core physician services, having exited most affiliated office-based practices in 2024.

Why It Matters

This filing signals a significant operational stabilization for Pediatrix Medical Group, moving from a substantial loss to a profit, which is crucial for investor confidence. The improved cash position provides greater financial flexibility for future investments or debt reduction, potentially strengthening its competitive stance against other healthcare providers. For employees, a more financially stable company could mean greater job security and potential for growth. Customers might benefit from a more focused service offering as the company streamlines its operations, though the revenue decline warrants close monitoring of market share and service demand.

Risk Assessment

Risk Level: medium — While Pediatrix reported a significant net income turnaround, net revenue declined by 5.99% for the nine months ended September 30, 2025, to $1.420 billion, indicating ongoing top-line challenges. The company's reliance on government and contracted managed care for 95% of its net patient service revenue exposes it to regulatory and reimbursement risks. Additionally, the company still carries a retained deficit of $116.835 million as of September 30, 2025.

Analyst Insight

Investors should consider MD as a potential turnaround play, but monitor future revenue trends closely. The strong cash flow from operations and absence of major impairment charges are positive, but sustained revenue growth is essential for long-term value creation. A 'hold' rating is appropriate until a clear path to revenue expansion is demonstrated.

Financial Highlights

debt To Equity

N/A

revenue

$1.420B

operating Margin

11.27%

total Assets

$1.70B

total Debt

N/A

net Income

$131.705M

eps

$1.53

gross Margin

N/A

cash Position

$340.059M

revenue Growth

-5.99%

Revenue Breakdown

Key Numbers

• $131.705M — Net Income (Nine months ended Sep 30, 2025, a swing from -$129.549M loss in 2024)
• $1.420B — Net Revenue (Nine months ended Sep 30, 2025, down from $1.511B in 2024)
• $340.059M — Cash and Cash Equivalents (As of Sep 30, 2025, up from $229.940M at Dec 31, 2024)
• $160.019M — Income from Operations (Nine months ended Sep 30, 2025, a significant improvement from -$108.004M loss in 2024)
• $71.708M — Net Income (Three months ended Sep 30, 2025, up from $19.441M in 2024)
• 5.99% — Revenue Decline (Nine months ended Sep 30, 2025, compared to the same period in 2024)
• $156.989M — Net Cash Provided by Operating Activities (Nine months ended Sep 30, 2025, up from $73.563M in 2024)
• 85,877,386 — Shares Outstanding (As of October 30, 2025)
• 95% — Net Patient Service Revenue from Contracted/Government Payors (For the nine months ended Sep 30, 2025)
• $116.835M — Retained Deficit (As of September 30, 2025)

Key Players & Entities

• Pediatrix Medical Group, Inc. (company) — registrant
• New York Stock Exchange (regulator) — exchange where MD is registered
• $131.705 million (dollar_amount) — net income for nine months ended September 30, 2025
• $129.549 million (dollar_amount) — net loss for nine months ended September 30, 2024
• $1.420 billion (dollar_amount) — net revenue for nine months ended September 30, 2025
• $1.511 billion (dollar_amount) — net revenue for nine months ended September 30, 2024
• $340.059 million (dollar_amount) — cash and cash equivalents as of September 30, 2025
• $229.940 million (dollar_amount) — cash and cash equivalents as of December 31, 2024
• SEC (regulator) — Securities and Exchange Commission
• Bloomberg (company) — publisher

FAQ

Risk Factors

• Dependence on Contracted Physicians [medium — operational]: The company relies on affiliated professional contractors to provide physician services. Changes in these contractual relationships or the availability of qualified physicians could materially impact operations and financial results. The company has exited most affiliated office-based practices in 2024, shifting focus to core physician services.
• Government Reimbursement Changes [high — regulatory]: A significant portion of revenue, 95% for the nine months ended September 30, 2025, comes from contracted/government payors. Changes in reimbursement rates or policies by these entities could adversely affect revenue and profitability.
• Joint Venture Performance [medium — financial]: The company has a 37.5% economic interest in a joint venture accounted for under the equity method. The performance of this venture and the company's ability to influence it are critical. The financial results of this venture are not fully consolidated.
• Transition from Office-Based Practices [medium — operational]: The company exited most affiliated office-based practices in 2024. While this streamlines focus, the transition and integration of remaining services could present operational challenges and impact revenue streams.
• Compliance with Healthcare Regulations [high — regulatory]: As a healthcare provider, the company is subject to extensive federal, state, and local regulations, including those related to patient care, billing, and privacy. Non-compliance can lead to significant penalties and reputational damage.

Industry Context

Pediatrix Medical Group operates in the highly competitive healthcare services sector, specifically focusing on physician services. The industry is characterized by evolving reimbursement models, increasing regulatory scrutiny, and a growing demand for specialized pediatric care. Consolidation among providers and shifts towards value-based care are key trends impacting companies like Pediatrix.

Regulatory Implications

The company faces significant regulatory risks inherent in the healthcare industry. Compliance with billing, coding, patient privacy (HIPAA), and quality standards is paramount. Changes in government healthcare policies and reimbursement rates from Medicare and Medicaid can materially affect revenue and profitability.

What Investors Should Do

1. Monitor revenue trends closely.
2. Analyze the impact of the joint venture.
3. Assess operational efficiency post-practice divestitures.
4. Evaluate the sustainability of profitability.

Key Dates

• 2025-09-30: End of Nine-Month Period — Reported significant net income turnaround and strong operating cash flow, though revenue declined.
• 2025-09-30: Consolidated Balance Sheet Date — Showcased an increase in cash and cash equivalents to $340.059 million.
• 2024-12-31: Prior Year End Balance Sheet Date — Cash and cash equivalents were $229.940 million.
• 2024-01-01: Start of Fiscal Year — The company began the year with a focus on core physician services after exiting most affiliated office-based practices.

Glossary

Affiliated professional contractors

Separate legal entities that provide physician services, often through contractual management arrangements with the company. (These entities are crucial for the company's service delivery model, and their performance and contractual relationships directly impact the company's results.)

Goodwill impairment

A charge taken when the carrying value of goodwill on the balance sheet exceeds its fair value, indicating a loss in value of an acquired business. (The absence of a $154.243 million goodwill impairment in 2025 significantly contributed to the reported net income improvement compared to 2024.)

Long-lived asset impairment

A charge recognized when the carrying amount of a long-lived asset (like property or equipment) is not recoverable, exceeding its fair value. (The absence of a $27.791 million long-lived asset impairment in 2025 also positively impacted the current period's net income.)

Equity method of accounting

An accounting method where an investment in another company is initially recorded at cost and then adjusted to recognize the investor's share of the investee's net income or loss. (The company uses this for its 37.5% owned joint venture, meaning only its share of the JV's profit or loss is reflected in the company's income statement, not the JV's full financials.)

Retained Deficit

The cumulative net losses of a company that have not been offset by net income over time, resulting in a negative balance in the retained earnings account. (The company still has a retained deficit of $116.835 million as of September 30, 2025, despite recent profitability, indicating a history of cumulative losses.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Pediatrix Medical Group has achieved a remarkable turnaround, moving from a net loss of $129.549 million to a net income of $131.705 million. This was primarily driven by the absence of significant goodwill and long-lived asset impairments recorded in 2024. However, net revenue has decreased by 5.99% to $1.420 billion, indicating a challenge in top-line growth despite improved profitability. Cash and cash equivalents have substantially increased to $340.059 million, supported by strong operating cash flow, which more than doubled from $73.563 million to $156.989 million.

Filing Documents

• md-20250930.htm (10-Q) — 1852KB
• md-ex31_1.htm (EX-31.1) — 15KB
• md-ex31_2.htm (EX-31.2) — 15KB
• md-ex32_1.htm (EX-32.1) — 9KB
• img261196317_0.jpg (GRAPHIC) — 309KB
• 0001193125-25-261640.txt ( ) — 6818KB
• md-20250930.xsd (EX-101.SCH) — 869KB
• md-20250930_htm.xml (XML) — 745KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 3 Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 (Unaudited) 3 Consolidated Statements of Income and Comprehensive Income for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited) 4 Consolidated Statements of Equity for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited) 5 Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 (Unaudited) 6

Notes to Consolidated Financial Statements (Unaudited)

Notes to Consolidated Financial Statements (Unaudited) 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 13 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 21 Item 4.

Controls and Procedures

Controls and Procedures 21

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 22 Item 1A.

Risk Factors

Risk Factors 22 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 22 Item 5. Other Information 22 Item 6. Exhibits 23

SIGNATURES

SIGNATURES 24 2 P e diatrix Medical Group, Inc. Consolidated Balance Sheets (in thousands, except share data) (Unaudited) September 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 340,059 $ 229,940 Short-term investments 123,042 118,566 Accounts receivable, net 231,122 259,990 Prepaid expenses 8,942 13,410 Income taxes receivable 3,815 12,614 Other current assets 10,215 5,087 Total current assets 717,195 639,607 Property and equipment, net 38,636 39,172 Goodwill 1,255,423 1,242,606 Intangible assets, net 14,802 11,595 Operating and finance lease right-of-use assets 35,702 39,267 Deferred income tax assets 79,758 103,855 Other assets 57,889 76,598 Total assets $ 2,199,405 $ 2,152,700 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable and accrued expenses $ 352,233 $ 398,690 Current portion of debt and finance lease liabilities, net 25,339 20,545 Current portion of operating lease liabilities 12,226 12,704 Income taxes payable 2,749 2,171 Total current liabilities 392,547 434,110 Long-term debt and finance lease liabilities, net 577,169 597,119 Long-term operating lease liabilities 27,533 31,945 Long-term professional liabilities 239,679 257,455 Deferred income tax liabilities 38,285 34,246 Other liabilities 33,526 32,887 Total liabilities 1,308,739 1,387,762 Commitments and contingencies Shareholders' equity: Preferred stock; $ .01 par value; 1,000,000 shares authorized; none issued — — Common stock; $ .01 par value; 200,000,000 shares authorized; 85,832,837 and 85,866,000 shares issued and outstanding, respectively 858 859 Additional paid-in capital 1,006,197 1,013,690 Accumulated other comprehensive income (loss) 446 ( 1,071 ) Retained deficit ( 116,835 ) ( 248,540 ) Total shareholders' e

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements September 30, 2025 (Unaudited) 1. Basis of Presentation and New Accounting Pronouncements: The accompanying unaudited Consolidated Financial Statements of the Company and the notes thereto presented in this Form 10-Q have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission ("SEC") applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America ("GAAP") for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results of interim periods. The financial statements include all the accounts of Pediatrix Medical Group, Inc. and its consolidated subsidiaries (collectively, "PMG") together with the accounts of PMG's affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (the "affiliated professional contractors"). Certain subsidiaries of PMG have contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states. The terms "Pediatrix" and the "Company" refer collectively to Pediatrix Medical Group, Inc., its subsidiaries and the affiliated professional contractors. During 2024, the Company exited almost all of its affiliated office-based practices, including its primary and urgent care service line. The operating results of these practices did not meet the criteria to be reported as discontinued operations in the Company ' s Consolidated Statements of Income and Comprehensive Income. The Company is a party to a joint venture in which it owns a 37.5 % economic interest. The Company accounts for this joint venture under the equity method of accounting becau

View Full Filing

View this 10-Q filing on SEC EDGAR